Table 2.
Ongoing randomized trials of immunotherapy in patients with advanced HCC
| Drug | Phase | Setting | Primary endpoint | ClinicalTrials.gov identifier |
|---|---|---|---|---|
| Nivolumab and ipilimumab vs. sorafenib/Lenvatinib | III | First-line | OS | NCT04039607 |
| Finotonlimab (anti PD-1) and SCT510 (bavacizumab) vs. sorafenib | II/III | First-line | OS, PFS | NCT04560894 |
| Toripalimab and lenvatinib vs. lenvatinib | III | First-line | OS | NCT04523493 |
| Nofazinlimab (CS1003) and lenvatinib vs. Lenvatinib | III | First-line | OS | NCT04194775 |
| Atezolizumab and lenvatinib or sorafenib vs. lenvatinib/sorafenib | III | Second-line | OS | NCT04770896 |
| Pembrolizumab and bavituximab | II | First-line | ORR | NCT03519997 |
| Pembrolizumab and regorafenib | II | Second-line | ORR | NCT04696055 |
| Nofazinlimab and lenvatinib vs. lenvatinib | III | First-line | OS | NCT04194775 |
| Tislelizumab and regorafenib vs. regorafenib | II | First-line | Safety, ORR, PFS | NCT04183088 |
| Nivolumab and ipilimumab vs. sorafenib/lenvatinib | III | First-line | OS | NCT04039607 (CheckMate 9DW)* |
| Atezolizumab and lenvatinib/sorafenib vs. lenvatinib/sorafenib | III | Second-line | OS | NCT04770896 (IMbrave 251)* |
| IBI310 and sintilimab vs. sorafenib | III | First-line | OS, ORR | NCT04720716 |
HCC, hepatocellular carcinoma; OS, overall survival; PD-1, programmed cell death protein-1; PFS, progression-free survival; ORR, objective response rate.
*
Study name.